Latest Articles

Publication Date
Integrated Bioinformatics and Experimental Analysis Revealed Crosstalk Between IL-6, Autophagy, Ubiquitination, and Key miRNAs in Female Infertility: Insights from Ovarian Endometriosis and Polycystic Ovary Syndrome.

Female infertility, affecting millions worldwide, involves complex molecular mechanisms such as chronic inflammation, impaired cellular death, and protein regulation. This study explores how the cytokine IL-6, the autophagy marker LC3, …

Published: Oct. 28, 2025, midnight
Fallopian tube cavernous haemangioma found during the caesarean section of a woman with a history of endometriosis: a case report and literature review.

This case report describes the management of fallopian tube cavernous haemangioma discovered at caesarean section, and provides insight to the literature on this extremely rare benign vascular tumor with regard …

Published: Oct. 28, 2025, midnight
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 11:43 p.m.
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 10:53 p.m.
Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic - citybuzz -

Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic citybuzz -

Published: Oct. 27, 2025, 9:33 p.m.
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 9:13 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 27, 2025, 7:50 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Yahoo Finance

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Yahoo Finance

Published: Oct. 27, 2025, 7:33 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 27, 2025, 7:33 p.m.
Kissei Pharmaceutical’s Promising Phase III Study on Endometriosis Treatment - TipRanks

Kissei Pharmaceutical’s Promising Phase III Study on Endometriosis Treatment TipRanks

Published: Oct. 27, 2025, 6:32 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!